Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Daily News

Age Cutoffs for PFO Closure Deserve a Rethink, Researchers Urge

L.A. McKeown

October 15, 2024

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

News Opinion Editor's Corner

What’s Going to Be Hot at TCT 2023

Shelley Wood

October 19, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2022

Shelley Wood

October 03, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Opinion CV Team Dispatch

September 2021 News Roundup

L.A. McKeown

September 01, 2021

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Todd Neale

September 03, 2019

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Advertisement

Age Cutoffs for PFO Closure Deserve a Rethink, Researchers Urge

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

What’s Going to Be Hot at TCT 2023

TCTMD’s Top 10 Most Popular Stories for September 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

September 2021 News Roundup

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content